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Norovirus	 (NoV)	 is	 a	 major	 cause	 of	 gastroenteritis.	
NoV	genotype	 II.4	 (GII.4)	 is	 the	predominant	genotype	 in	
health	 care	 settings	 but	 the	 reason	 for	 this	 finding	 is	 un-
known.	Stool	samples	containing	isolates	with	a	known	NoV	
genotype	from	2,109	patients	in	Denmark	(patients	consult-
ing a general practitioner or outpatient clinic, inpatients, and 
patients	from	foodborne	outbreaks)	were	used	to	determine	
genotype	 distribution	 in	 relation	 to	 age	 and	 setting.	 NoV	
GII.4	was	more	prevalent	among	inpatients	than	among	pa-
tients in community settings or those who became infected 
during foodborne outbreaks. In community and health care 
settings, we found an association between infection with 
GII.4	 and	 increasing	 age.	 Norovirus	 GII.4	 predominated	
in	patients	≥60	years	of	age	and	in	health	care	settings.	A	
larger proportion of children than adults were infected with 
NoV	GII.3	or	GII.P21.	Susceptibility	to	NoV	infection	might	
depend	on	patient	age	and	infecting	NoV	genotype.	Cohort	
studies are warranted to test this hypothesis.
Norovirus (NoV) is a major cause of viral gastroen-teritis (1) and a common cause of outbreaks of acute 
gastroenteritis in institutional settings, such as hospitals, 
nursing homes, and schools. Foodborne outbreaks of NoV 
infection are also common (2,3).
NoVs are positive-sense, single-stranded, non-envel-
oped RNA viruses (4). On the basis of amino acid or nu-
cleotide sequencing of the polymerase and capsid regions, 
NoV can be divided into 6 genogroups (GI–GVI) and sev-
eral genotypes. GI, GII, and GIV are human pathogens 
(5–7). Recombination events within a genogroup are com-
mon (8). Thus, genotyping of NoV should ideally be based 
on sequencing of the capsid and polymerase regions of the 
viral genome (9).
NoV sequences reported to the Foodborne Viruses in 
Europe Network come from mainly foodborne outbreaks 
or outbreaks in health care settings (2). Outbreaks in health 
care settings are most often caused by NoV genogroup II 
genotype 4 (GII.4) (10–13). The proportion of outbreaks 
caused by GII.4 is lower in non–health care settings 
(2,3,12,14). Elderly persons seem to be more susceptible 
to NoV infection (15,16). This susceptibility has been sug-
gested to be genotype dependent (3).
The purpose of this study was to describe the distribu-
tion of NoV genotypes among infections in patients consult-
ing a general practitioner (GP) or outpatient clinic, patients 
in health care settings, and patients in foodborne outbreaks. 
The association between NoV GII.4 and age of the patients 
in community and health care settings was also determined.
Materials and Methods
Patient Samples
The study included patients who had stool samples 
test positive for NoV during routine diagnostic virus 
analyses at the Department of Virology at Statens Serum 
Institut, Copenhagen, Denmark, during 2006–2010. This 
department serves as a reference laboratory and, through-
out the study period, also served as the primary virus di-
agnostic laboratory for most GPs, outpatient clinics, and 
hospitals in Denmark. Information about sampling date, 
setting (i.e., hospital, GP, or outpatient clinic), age, and sex 
of the patients was obtained from the laboratory database. 
Samples from patients infected during suspected foodborne 
outbreaks of gastroenteritis were accompanied by special 
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request forms at submission to the laboratory. Information 
regarding hospital admissions (dates and wards) during 
the study period was obtained from the Danish Health and 
Medicines Authority. Patients registered in the laboratory 
database as inpatients were excluded if hospitalization at 
the time of sampling could not be verified. Collection and 
registration of patient data were approved by the Danish 
Data Protection Agency (record nos. 2012–54–0046 and 
2010–54–1076).
Using the personal identification numbers mandatory 
for all Danish citizens, we obtained postal addresses for 
patients ≥60 years of age who were positive for NoV and 
had a sample with an assigned genotype submitted from 
an outpatient clinic or GP. The addresses were used to de-
termine if these patients were nursing home residents as of 
July 2013. Patients who had died before July 2013 were 
excluded because it was not possible to determine if they 
had been nursing home residents (n = 21).
Patient NoV samples were obtained from 3 settings. 
The first group consisted of inpatients and nursing home 
residents (referred to as health care settings), the second 
group consisted of patients consulting a GP or outpatient 
clinic (referred to as community settings), and the third 
group consisted of patients from foodborne outbreaks. The 
patients were from all 5 regions of Denmark.
Sampling and admission dates were used to estimate 
whether infections were nosocomial or community ac-
quired. An infection was classified as community acquired 
if stool samples were obtained on the day of admission or 
the following day, nosocomial if samples were obtained 
on day 5 or afterwards, and indeterminate if samples were 
obtained between these 2 periods. Multiple samples were 
submitted from 1,060 patients. To avoid overrepresentation 
of patients chronically infected with NoV, only the first 
NoV-positive sample from each patient was included. Dur-
ing the study period, samples were continuously selected 
for genotyping. The intention was to type all samples from 
community settings, ≥1 sample from every hospital ward 
per month, and 1 sample from each foodborne outbreak, 
respectively, which yielded 2,231 samples.
RNA Extraction
Stool samples were processed as 10% (wt/vol) suspen-
sions in phosphate buffer solution, centrifuged at 4°C for 
30 min at 3,400 g, and analyzed within 72 h of arrival. Nu-
cleic acids were extracted by using MagNa Pure LC (Roche 
Diagnostics, Hvidovre, Denmark) and the Viral NA Small 
Volume Kit (Roche Diagnostics) according to the manu-
facturer’s instructions.
Real-time Reverse Transcription PCR
NoV GI and GII were detected by real-time reverse 
transcription PCR (RT-PCR) by using the OneStep RT-
PCR Kit (QIAGEN, Aarhus, Denmark) and primers and 
probes, as previously described (17). PCR conditions are 
shown in the online Technical Appendix (http://wwwnc.
cdc.gov/EID/article/20/7/13-0781-Techapp1.pdf).
NoV Genotyping
Polymerase RT-PCR
Polymerase gene sequences were obtained by using 
primers JV12Y-JV13 (18) or JV12BH-NVp110 (18,19) 
in 1 round of amplification. If PCR results were nega-
tive, a nested PCR was performed (20). Using the above-
mentioned primers, we performed an RT-PCR with the 
OneStep RT-PCR Kit (QIAGEN) for the first-round PCR 
and AmpliTaq 360 DNA Polymerase (Applied Biosystems, 
Naerum, Denmark) for second-round PCR according to the 
manufacturers’ instructions. PCR conditions are shown in 
the online Technical Appendix.
Capsid RT-PCR
Capsid gene sequences were obtained by using a semi-
nested GI-specific primer set (GIFF-1, GIFF-2, and GIFF-
3 for a first-round PCR and GISKR [GIFFN and GISKR] 
for a second-round PCR), which amplified 305 bp of the GI 
capsid gene; or a semi-nested GII-specific primer set (G2FB-
1, G2FB-2, and G2FB-3 for a first-round PCR and G2FBN 
[COG2F and G2SKR] for a second-round PCR), which am-
plified 299 bp of the GII capsid gene (17,21,22). Using these 
primers, we performed an RT-PCR by using the OneStep 
RT-PCR Kit (QIAGEN) for a first-round PCR and Ampli-
Taq 360 DNA Polymerase (Applied Biosystems) for a sec-
ond-round PCR according to the manufacturers’ instructions. 
PCR conditions are shown in the online Technical Appendix.
Sequencing
PCR products were prepared for sequencing by using 
Exo-SAP (GE Healthcare, Little Chalfont, UK) according 
to the manufacturer’s instructions. Both strands of DNA 
were sequenced by using an ABI 377 DNA Sequencer (Ap-
plied Biosystems) with the same primers used for RT-PCR 
and the Big Dye Terminator Kit 1.1 (Applied Biosystems).
Sequence Analysis and Identification of Genotype
Sequence analysis and assembly were performed by 
using BioNumerics version 6.6 (Applied Maths, Sint-Mar-
tens-Latem, Belgium). Genotypes were assigned by using 
phylogenetic analyses (http://www.rivm.nl/mpf/norovirus/
typingtool) (6). Genotyping was primarily based on the 
polymerase sequence. If this procedure was not successful, 
sequencing of the capsid genome was attempted. For some 
sample gene products, both regions were sequenced. If di-
vergent genotypes were detected in the capsid and poly-
merase genes, the capsid genotype was used.
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Descriptive Analyses
Distribution of patients with respect to age and setting 
was initially determined by using all 3,848 samples. To ob-
tain a representative picture of the distribution of circulat-
ing NoV genotypes and to avoid including several patients 
from the same outbreak, we included only the first sample 
from each clinic and ward within a calendar month (n = 
1,612). The difference in age between patients with and 
without an assigned genotype was obtained for community 
and health care settings separately by using the Wilcoxon-
Mann-Whitney test. The association between an assigned 
genotype (as the outcome) and age and sex (separately) was 
evaluated by using univariable logistic regression analysis. 
The association between genotype and age group was test-
ed by using the Pearson χ2 test.
Association between NoV GII.4 and Patient Age
The association between age and infection with NoV 
GII.4 was measured by using multilevel logistic regression 
analysis. Patients grouped within the same cluster (ward 
or clinic) are often more similar than randomly selected 
patients from different clusters. To account for this lack 
of independence between patients in clusters, a multilevel 
model was used that assumed a normal distribution of ran-
dom effects. A total of 523 clusters (212 wards and 311 
clinics) were included. The outcome was NoV genotype 
as the binary variable (GII.4 or non-GII.4). Three covari-
ates were included in the analysis as fixed effects: age (<3, 
3–19, 20–39, 40–59, and ≥60 years), setting (community 
or health care), and sex. Two interactions were considered 
of interest and were included in the analyses; these were 
the interactions between setting and age and between set-
ting and sex. Backward elimination was used to exclude 
non-significant interactions by first removing the most non-
significant interaction.
The mean cluster size was 3.73 (range 1–55). To 
evaluate the effect of a small cluster size, the analysis was 
repeated by including only clusters (i.e., wards and clin-
ics) with >5 patients in the analysis. The analysis was also 
repeated by using logistic regression without any random 
effect on the descriptive dataset shown in Table 1 (i.e., first 
patient with an assigned genotype from each clinic and 
ward within a calendar month).
Stata software version 11.2 (StataCorpLP, College 
Station, TX, USA) and SAS version 9.3 (SAS Institute, 
Cary, NC, USA) were used for analyses. Significance was 
determined at p<0.05 and by using 2-sided tests.
Results
During the 5-year study period, stool samples from 
18,796 patients were submitted to the Department of Vi-
rology at Statens Serum Institut. A total of 4,056 patients 
were positive for NoV. After exclusion of patients with 
uncertain hospitalization status, 3,848 patients were in-
cluded for further analysis (Table 1). These patients were 
from 230 wards in 60 hospitals in Denmark, 356 general 
practices or outpatient clinics, and 46 suspected foodborne 
outbreaks. A NoV genotype was identified for 2,109 pa-
tients. Of these patients, 1,713 had samples initially se-
lected for genotyping. In 223 of the selected samples, a 
genotype was not obtained because of lack of sensitivity 
or sample material; genotyping was not attempted for 295 
other samples.
A genotype based on sequence information from the 
polymerase and the capsid genes was obtained for NoVs in 
349 (17%) samples. NoVs from 1,496 (71%) samples were 
genotyped by partial sequencing of the polymerase gene 
and NoVs from 264 (13%) samples were genotyped by par-
tial sequencing of the capsid gene. Thus, a genotype was 
established for NoVs in samples from 204 (89%) wards, 
59 (98%) hospitals, and 313 (88%) clinics. A genotype 
was established for NoVs in ≥1 sample from all foodborne 
outbreaks. The age distribution differed significantly be-
tween patients for whom an NoV genotype was identified 
and those for whom it was not (community settings: p = 
0.002; health care settings: p<0.001. However, when we 
compared patients ≥60 years of age in community settings 
with patients <3 years of age, the proportion of genotyped 
NoVs in samples did not differ significantly (odds ratio 0.6, 
95% CI 0.4–1.1, p = 0.1).
Among the 2,109 patients for whom the infectious 
agent had an assigned NoV genotype, 882 patients were 
 
Table	1.	Age	and	setting	for	3,848	patients	with	stool	samples	positive	for	norovirus,	Denmark,	2006–2010* 
Age group, y 
All	patients,	no.	(%) 
 Descriptive analysis,† no. (%)  
patients positive for GII.4)‡ 
Community	
settings 
Health	care	
settings 
Foodborne	
outbreaks 
 Community	
settings 
Health	care	
settings 
Foodborne	
outbreaks 
<3 680	(61) 36	(1) NR  490	(51) 23	(57) NR	 
3–19 113	(10) 15	(1) NR	  71	(27) 10	(50) NR	 
20–39 145	(13) 76	(3) NR	  94	(62) 33	(64) NR	 
40–59 93	(8) 240	(9) NR	  64	(64) 90	(89) NR	 
≥60 86	(8) 2,196	(86) NR	  62	(82) 629	94) NR 
Total 1,117	(100) 2,563	(100) 168	(100)  781	(54) 785	(91) 46	(41) 
*Only	1	sample	per	patient	was	included.	GII,	genogroup	II;	NR,	not	relevant. 
†Only 1 patient per clinic or ward per month was included. 
‡Proportion	of	patients	infected	with	novovirus	GII.P4	or	G.II.4	in	each	age	group. 
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from community settings, 1,070 were from health care set-
tings, and 157 were from foodborne outbreaks. Patients 
from health care settings were further grouped into noso-
comially infected patients (n = 539), patients with commu-
nity-acquired infections (n = 248), patients with an inde-
terminate source of infection (n = 274), and nursing home 
residents (n = 9).
A total of 22 NoV capsid and 15 polymerase genotypes 
were detected among the genotyped samples. In patients from 
community settings, 20 capsid and 12 polymerase genotypes 
were detected, and 14 capsid and 8 polymerase genotypes 
were detected in NoVs from patients in health care settings. 
With the exception of GII.21, all NoV genotypes detected 
in health care settings were also detected in community set-
tings. Among the samples from the 46 foodborne outbreaks, 
15 NoV capsid and 11 polymerase genotypes were detected. 
The 2 most prevalent genotype combinations were GII.P21_
GII.3 and GII.P7_GII.6, and the 6 most common genotypes 
were GII.P4, GII.4, GII.6, GII.3, GII.P21, and GII.7 (Figure 
1). Clinics (n = 60) and wards (n = 63) that were represented 
with ≥5 patients with an assigned genotype had median pro-
portions of NoV GII.4 of 57% (range 14%–100%) and 96% 
(range 17%–100%), respectively.
The age distribution differed considerably between 
patients from community and health care settings (Table 
1). A significantly larger proportion of patients from health 
care settings were ≥60 years of age (2,196/2,563, 86%) 
(p<0.001). In contrast, patients from community settings 
were mainly children <3 years of age (680/1,117, 61%) 
(p<0.001).
Descriptive Analyses
In these analyses, only 1 patient per calendar month 
from each GP, outpatient clinic, and ward was included 
(Table 1). Foodborne outbreaks were described on an out-
break level with only 1 sample representing each outbreak 
(n = 46 outbreaks).
The distribution of NoV genotypes according to age 
and setting is shown in Figure 2. The distribution differed 
between community and health care settings. Although 
most patients from health care settings were infected with 
GII.4 (712/785, 91%), this genotype was detected in a sig-
nificantly lower proportion of patients from community 
settings (421/781, 54%) (p<0.001). The proportion infect-
ed with GI was significantly higher in foodborne outbreaks 
(22%) than in community settings (6%) and health care 
settings (2%) (p<0.001). When samples positive for NoV 
GII.4 and GII.P4 were excluded, the proportion of GI was 
similar for those infected in community (13%) and health 
care settings (16%) but significantly higher for those in-
fected in foodborne outbreaks (37%) (p = 0.001).
The proportion of children <3 years of age infected with 
NoV GII.3 or GII.P21 ranged from 11% to 25% during the 
study period. However, ≤3% of adults ≥60 years of age were 
positive for these genotypes. This difference was significant 
for each year studied (each year tested:  p<0.001).
Association between NoV GII.4 and Patient Age
When we compared with younger and older infected 
persons, we found a strong association between infection 
with NoV GII.4 and patient age ≥60 years in community 
and health care settings. This association was greater in 
health care settings than in community settings (Table 
2) (p<0.001 for effect of age and setting). The mean 
Figure	1.	Distribution	of	norovirus	genotypes	of	isolates	from	stool	
samples	of	A)	patients	in	community	settings	(n	=	781	samples),	B)	
patients	in	health	care	settings	(n	=	785	samples),	and	C)	patients	
in	 foodborne	outbreaks	 (n	=	46	samples),	Denmark,	2006–2010.	
From	each	clinic	and	hospital	ward,	only	 the	first	sample	with	an	
assigned	 genotype	 per	 calendar	 month	 is	 included.	 Values	 in	
parentheses	are	numbers	of	 isolates	with	a	specific	genotype	or	
genogroup.
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proportion of NoV GII.4 within each ward or clinic with 
respect to the mean patient age is shown in Figure 3. The 
sensitivity analysis showed similar results regarding odds 
ratios (Table 2).
Discussion
In this study of 3,846 patients who were positive for 
NoV by routine diagnostic procedures for gastroenteritis 
in Denmark during 2006–2010, we detected an association 
between an age ≥60 years and infection with NoV GII.4 
in patients from community and health care settings. We 
also found that NoV GII.P21/GII.3 was more prevalent in 
children than in adults, and NoV GI was more frequently 
detected in patients from foodborne outbreaks than in pa-
tients from community and health care settings.
NoV GII.4 was the most prevalent genotype among 
patients in health care settings (in 91%). However, only 
54% of patients from community settings were infected 
with this genotype. This finding is consistent with findings 
in a recent study from the United States, which reported 
that 84%–87% of outbreaks in hospitals and long-term care 
facilities were caused by GII.4 compared with 17%–75% 
in other settings (13). The reason for the predominance 
of GII.4 in health care settings has been debated. Patient 
characteristics, such as increased susceptibility caused by 
concurrent illnesses or older age, have been suggested (3). 
Virus characteristics, such as greater inherent virulence or 
increased virus shedding, thereby facilitating transmission 
in settings with a high concentration of persons, have also 
been suggested as contributing factors (2,23). A study by 
Vega et al. reported that older age was associated with GII.4 
outbreaks in diverse settings, such as schools, restaurants, 
and hospitals (13). Our study confirmed this association, 
which was present in community and health care settings 
and could partly explain the predominance of GII.4 in hos-
pital settings. The association was stronger for patients in 
health care settings than for patients in community settings, 
but the reason for this difference is unknown. Once intro-
duced into a hospital setting, NoV GII.4 might be more eas-
ily transmitted than other genotypes, thus infecting elderly 
patients already hospitalized for other reasons (2).
Other studies compared the clinical manifestations of 
infection with NoV GII.4 with those of infection with other 
NoV genotypes. Two studies of persons in nursing homes 
showed that symptoms were more severe in persons in-
fected with GII.4 than in persons infected with other NoV 
Figure	2.	Distribution	of	norovirus	genotypes	by	patient	age	and	setting	for	1,566	patients	positive	for	norovirus,	Denmark,	2006–2010.	
Only	1	patient	from	each	general	practice	or	outpatient	clinic	(n	=	781	patients)	and	ward	(n	=	785	patients)	within	a	calendar	month	were	
included	(foodborne	outbreak	patients	were	not	 included).	 Inpatients	and	patients	from	nursing	homes	were	grouped	as	patients	from	
health	care	settings.	Genogroup	I	(GI),	blue;	GII.P21,	gold;	GII.3,	orange;	GII.4	or	GII.P4,	red;	GII.6,	purple;	GII.P7,	pink;	GII.7,	brown;	all	
other	genogroup	II,	green.	C,	community;	H,	health	care.	
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genotypes (24,25). This finding could be caused by the age 
of the participants, a finding consistent with the results of our 
study. A study of NoV infections in newborns, whom the 
authors presumed to have no pre-existing immunity, showed 
that the length of symptomatic NoV infection was longer 
when newborns were infected with NoV GII.4 than with 
other genotypes (23). This finding differs from the hypoth-
esis that only elderly persons have more severe infections 
when infected with NoV GII.4 than with other genotypes. 
Because an association between persons ≥60 years of age 
and infection with NoV GII.4 was also observed in patients 
from community settings in our study, the increased dura-
tion of symptomatic NoV GII.4 infection in infants could be 
caused by immaturity of their immune systems. Desai et al. 
conducted a literature review of published NoV outbreaks 
and concluded that in community settings and long-term 
care facilities, incidence of hospitalization and death was 
increased during infection with NoV GII.4 compared with 
non–GII.4 NoV (26). These findings support the theory that 
the high proportion of GII.4 in hospital settings is caused 
by viral characteristics rather than host characteristics. How-
ever, Desai et al. did not control for age, which might have 
biased the results toward an increased risk for hospitalization 
during infection with NoV GII.4.
We determined that NoV GI was more prevalent in 
foodborne outbreaks than in outbreaks in health care and 
community settings, which is consistent with previous stud-
ies that reported that GI is more frequently observed in food-
borne NoV outbreaks than in outbreaks involving person-to-
person transmission (2,3). Excluding GII.4, the proportion of 
GI was similar in health care and community settings.
When we grouped GII.3 and GII.P21, we observed 
a higher proportion of these genotypes in young children 
than among patients ≥60 years of age. This finding is con-
sistent with those of other studies, which indicate that GII.
P21 (formerly classified as GII.b) and GII.3 infect mainly 
young children (10,27–29). It has been hypothesized that 
genotypes that preferentially infect young children, such as 
GII.3, require less antigenic variation because of the con-
stant renewal of the host population with persons who do 
not have established immune-associated protection from 
previous infections (30). This situation is in contrast to that 
for GII.4, which infects a large proportion of the adult pop-
ulation and thus requires a constant change in host-binding 
receptors to evade the immune response.
Our study had several limitations. First, sampling bias 
was caused by inclusion of samples collected for routine di-
agnostic virus analyses, rather than a cohort encompassing 
all cases of acute gastroenteritis. Generally, only a few pa-
tients in hospital outbreaks of infectious gastroenteritis in 
Denmark are diagnosed by laboratory testing. We assume 
that most hospitalized patients with community-acquired 
 
Table	2.	Association	between	age	and	infection	with	norovirus	GII.4,	Denmark,	2006–2010* 
Variable 
All patients with an assigned genotype, n	=	1,952 
 
Sensitivity	analysis	1,	
n	=	1,299	patients 
 
Sensitivity analysis 2, 
n	=	1,566	patients 
Total no. 
(%)† 
No.	(%) positive 
for GII.4‡ OR 95%	CI OR 95%	CI OR 95%	CI 
Community	settings           
 Age, y           
  <3 558	(63) 291	(52) 0.60 0.39–0.91  0.46 0.25–0.86  0.63 0.40–1.00 
  3–19 80	(9) 21	(26) 0.19 0.10–0.37  0.09 0.03–0.24  0.22 0.11–0.43 
  20–39 114	(13) 73	(64) Ref NA  Ref NA	  Ref NA	 
  40–59 66	(7) 43	(65) 1.03 0.54–1.95  0.86 0.30–2.42  1.07 0.55–2.08 
  ≥60 64	(7) 53	(83) 2.71 1.27–5.78  2.23 0.73–6.88  2.86 1.32–6.19 
Health	care	settings           
 Age, y           
  <3 25	(2) 13	(52) 0.46 0.16–1.29  0.50 0.13–1.98  0.75 0.25–2.22 
  3–19 12	(1) 6	(50) 0.41 0.11–1.52  0.23 0.04–1.19  0.58 0.14–2.41 
  20–39 44	(4) 31	(71) 1	(Ref) NA	  1	(Ref) NA	  1	(Ref) NA	 
  40–59 119	(11) 107	(90) 3.73 1.54–9.05  3.42 1.20–9.72  4.59 1.75–12.09 
  ≥60 870	(81) 828	(95) 8.39 4.07–17.29  8.37 3.55–19.78  9.62 4.38–21.12 
 Sex           
  M 965	(49) 716	(74) 1.23 0.96–1.56  1.26 0.92–1.74  1.22 0.95–1.58 
  F 987	(51) 750	(76) Ref NA	  Ref NA	  Ref NA	 
   Estimate SE  Estimate SE  Estimate SE 
Variation	between	
clusters§ 
NA NA 0.053 0.089  0.062 0.101  NA	 NA	 
Intraclass correlation 
coefficient 
NA NA 2.6% NA	  1.95% NA	  NA	 NA	 
Dispersion parameter NA NA 0.99 NA	  0.99 NA	  1.01 NA	 
*Sensitivity analysis 1 was a multilevel logistic regression model that included only wards and clinics with ≥5 patients. Sensitivity analysis 2 was a logistic 
regression	model	(without	random	effect)	that	included	only	the	first	patient	per	month	within	each	ward	and	clinic.	GII,	genogroup	II;	OR,	odds	ratio;	Ref,	
referent;	NA,	not	applicable.	An	OR>1	indicates	an	increased	risk	for	norovirus	GII.4	infection	compared	with	patients	20–39	y	of	age. 
†Proportions for community settings do not add up to 100% because of rounding. 
‡Proportion of patients infected with norovirus GII.P4 or GII.4 in each age or sex group. 
§Estimated	to	be	1.12	(SE	0.18)	in	the	random	intercept-only	model	(i.e.,	without	the	effect	of	age,	sex,	and	setting). 
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NoV infection are tested for NoV as a differential diagno-
sis to bacterial causes of gastroenteritis, but this assump-
tion might not be correct. As in another study (31), our 
study had an overrepresentation of young and old persons. 
This overrepresentation could have affected the outcome 
because it is likely that severity of disease, concurrent ill-
nesses, and young age increase the probability of seeking 
medical attention. If elderly persons are more likely to be 
tested for NoV and GII.4 is more virulent than other NoV 
genotypes, the statistical results could be biased toward an 
increased effect of age on the odds of infection with GII.4. 
The best way of testing this hypothesis would be to conduct 
a cohort study that included all patients with gastroenteritis.
Second, genotyping of NoV isolates was only per-
formed for selected number of NoV-positive patients, but 
these samples represented almost 90% of all wards, GPs, 
and outpatient clinics submitting samples to the laboratory. 
The distribution of age differed between patients whose 
sample isolates had an assigned genotype. However, a no-
table finding was the association between NoV GII.4 and 
age ≥60 years old in community settings. The proportions 
of genotyped samples did not differ between patients ≥60 
and <3 years of age in community settings. Furthermore, 
we detected 22 NoV capsid and 15 polymerase genotypes, 
which made it unlikely that problems with laboratory meth-
ods systematically biased the results.
Third, we did not have epidemiologic data to compare 
the distribution of NoV genotypes at an outbreak level. 
Alternatively, the association between age and NoV GII.4 
was examined by including the random effect of clinics 
and wards. This feature was possible because of the large 
number of available clinics and wards (32). The associa-
tion between NoV GII.4 and age was also observed in sen-
sitivity analyses that included 1 patient per clinic or hos-
pital ward in each calendar month or included clinics and 
wards with ≥5 patients.
Fourth, we estimated that most hospitalized patients 
were nosocomially infected with NoV. This estimate was 
based on admission and sampling dates because clini-
cal data were not available. For some patients, sampling 
Figure	 3.	 Proportions	 of	 norovirus	
genogroups	 GII.4	 or	 GII.P4	 with	
respect to mean age of patients with 
an assigned genotype in each hospital 
ward	 (A)	 (n	 =	 212	 wards,	 1,070	
patients)	or	clinic	(B)	(n	=	311	clinics,	
882	 patients),	 Denmark,	 2006–2010.	
Regression	lines	are	indicated.
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may have been performed >1 day after onset of symptoms. 
Therefore, the proportion of nosocomially infected patients 
might have been overestimated.
In this retrospective study of NoV gastroenteritis in 
Denmark, we compared infections in patients from food-
borne outbreaks, community settings, and health care 
settings. Our results confirmed that most NoV genotypes 
circulating in health care settings were GII.4 and that in-
fection with NoV GII.P21 or II.3 was more prevalent in 
children than adults. We observed an association between 
older age and infection with NoV GII.4, which could partly 
explain why most NoV infections in health care settings are 
caused by this genotype. Cohort studies testing this hypoth-
esis would be of value.
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